Viewing Study NCT04596150

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 5:10 PM
Ignite Modification Date: 2026-01-22 @ 6:34 PM
Study NCT ID: NCT04596150
Status: COMPLETED
Last Update Posted: 2024-01-23
First Post: 2020-10-02
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
Sponsor: CytomX Therapeutics
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Neoplasms View
None Breast Neoplasms View
None Breast Neoplasms, Triple-Negative View
None Breast Cancer View
None Breast Neoplasms, Hormone Receptor Positive/HER2 Negative View
Keywords:

Keywords

Keyword Brief Keyword Text View
None HR-positive/HER2-non-amplified View
None HR+ View
None HER2 non-amplified View
None Hormone Receptor View
None N2'-deacetyl-N2'-(4-mercapto-4-methyl-1-oxopentyl)-maytansine (DM4) View
None Cluster of Differentiation 166 (CD166) View
None Triple negative breast cancer View
None Breast cancer View
None Probody View
None Armed antibody View
None Mytansine View
None Hormone Receptor Positive View
None DM4 View
None CD166 View
None PD-L1 View
None Praluzatamab Ravtansine View
None Pacmilimab View